Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Poignard

Showing results (21-30 of 84) with videos related to

Pageof 9
Sort By:
Journal of Virology|November 8, 2014
Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelopeKatie J Doores, Leopold Kong, Stefanie A Krumm, et al.
Journal of Virology|May 17, 2015
Correction for Doores et al., Two Classes of Broadly Neutralizing Antibodies within a Single Lineage Directed to the High-Mannose Patch of HIV EnvelopeKatie J Doores, Leopold Kong, Stefanie A Krumm, et al.
Journal of Leukocyte Biology|January 10, 2008
Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infectionLaura Adalid-Peralta, Véronique Godot, Céline Colin, et al.
Nature Medicine|June 16, 2009
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaquesAnn J Hessell, Pascal Poignard, Meredith Hunter, et al.
The Journal of Antimicrobial Chemotherapy|September 5, 2024
Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trialMaxime Beaulieu, Alexandre Gaymard, Clément Massonnaud, et al.
Plos One|August 31, 2013
A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1Johannes S Gach, Heribert Quendler, Tommy Tong, et al.
International Journal of Molecular Sciences|February 15, 2022
AKR1B10, One of the Triggers of Cytokine Storm in SARS-CoV2 Severe Acute Respiratory SyndromeClovis Chabert, Anne-Laure Vitte, Domenico Iuso, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 2012
Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivoBrian Moldt, Eva G Rakasz, Niccole Schultz, et al.
Journal of Virology|November 13, 2009
Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-LAnn J Hessell, Eva G Rakasz, David M Tehrani, et al.
Frontiers in Immunology|June 24, 2024
Revisiting the interaction between complement lectin pathway protease MASP-2 and SARS-CoV-2 nucleoproteinIsabelle Bally, Guillaume Drumont, Véronique Rossi, et al.
Pageof 9

Showing results (21-30 of 84) with videos related to

Sort By:
Pageof 9
Journal of Virology|November 8, 2014
Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelopeKatie J Doores, Leopold Kong, Stefanie A Krumm, et al.
Journal of Virology|May 17, 2015
Correction for Doores et al., Two Classes of Broadly Neutralizing Antibodies within a Single Lineage Directed to the High-Mannose Patch of HIV EnvelopeKatie J Doores, Leopold Kong, Stefanie A Krumm, et al.
Journal of Leukocyte Biology|January 10, 2008
Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infectionLaura Adalid-Peralta, Véronique Godot, Céline Colin, et al.
Nature Medicine|June 16, 2009
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaquesAnn J Hessell, Pascal Poignard, Meredith Hunter, et al.
The Journal of Antimicrobial Chemotherapy|September 5, 2024
Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trialMaxime Beaulieu, Alexandre Gaymard, Clément Massonnaud, et al.
Plos One|August 31, 2013
A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1Johannes S Gach, Heribert Quendler, Tommy Tong, et al.
International Journal of Molecular Sciences|February 15, 2022
AKR1B10, One of the Triggers of Cytokine Storm in SARS-CoV2 Severe Acute Respiratory SyndromeClovis Chabert, Anne-Laure Vitte, Domenico Iuso, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 2012
Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivoBrian Moldt, Eva G Rakasz, Niccole Schultz, et al.
Journal of Virology|November 13, 2009
Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-LAnn J Hessell, Eva G Rakasz, David M Tehrani, et al.
Frontiers in Immunology|June 24, 2024
Revisiting the interaction between complement lectin pathway protease MASP-2 and SARS-CoV-2 nucleoproteinIsabelle Bally, Guillaume Drumont, Véronique Rossi, et al.
Pageof 9